Key Developments: KaloBios Pharmaceuticals Inc (KBIO.OQ)

KBIO.OQ on NASDAQ Stock Exchange Global Market

2.01USD
28 Aug 2015
Change (% chg)

$0.04 (+2.03%)
Prev Close
$1.97
Open
$2.00
Day's High
$2.07
Day's Low
$1.98
Volume
1,204
Avg. Vol
11,967
52-wk High
$17.04
52-wk Low
$1.64

Search Stocks

Latest Key Developments (Source: Significant Developments)

KaloBios Pharmaceuticals, Inc appoints Executive Chairman
Thursday, 28 May 2015 04:01pm EDT 

KaloBios Pharmaceuticals, Inc:Appoints Ronald A. Martell, to position of Executive Chairman.  Full Article

KaloBios Pharmaceuticals Inc announces retirement of President and Chief Executive Officer
Thursday, 8 Jan 2015 04:31pm EST 

KaloBios Pharmaceuticals Inc:Says David W. Pritchard, president and chief executive officer, has decided to retire, effective immediately.Names Herb C. Cross, chief financial officer, as interim CEO pending a search for a new chief executive officer.  Full Article

KaloBios Pharmaceuticals reports top-line data for phase 2 study of KB001-a to treat pseudomonas aeruginosa lung infections in cystic fibrosis patients
Tuesday, 6 Jan 2015 04:01pm EST 

KaloBios Pharmaceuticals Inc:Announced top-line data from the randomized, double-blind, placebo-controlled Phase 2 study of KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, to treat Pseudomonas aeruginosa lung infections in subjects with cystic fibrosis.Says it also evaluated time to need for antibiotics in a number of pre-specified subgroup analyses known to be associated with such risk and none demonstrated an improvement for KB001-A versus placebo.  Full Article

publication by KaloBios Pharmaceuticals Inc and collaborators shows EphA3 as target for highly selective anticancer therapy
Thursday, 14 Aug 2014 08:00am EDT 

KaloBios Pharmaceuticals Inc:Announces publication of preclinical findings describing EphA3 as a novel target expressed by a broad range of human tumors, and whose activation can lead to the selective disruption of the tumor microenvironment and newly formed tumor blood vessels.The expression and function of EphA3 in the tumor microenvironment but not in adult normal tissues together with the favorable safety profile as observed thus far in a Phase 1-2 clinical study.  Full Article

KaloBios Pharmaceuticals Inc provides update on KB001-A partnership and clinical status
Monday, 28 Jul 2014 04:01pm EDT 

KaloBios Pharmaceuticals Inc:Provides an update on the status of the KB001-A development program, including an update on its KB001-A collaboration with Sanofi Pasteur.Reached an agreement with Sanofi Pasteur to regain all rights to KaloBios' KB001-A program.Under this agreement, the collaboration and licensing agreement entered into in 2010 has been terminated.Under that collaboration agreement, Sanofi Pasteur had been developing KB001-A, a patented monoclonal antibody targeting Pseudomonas aeruginosa ( Pa ).Says for Pa pneumonia prevention in the intensive care setting while KaloBios had been developing KB001-A for chronic treatment of Pa lung infections in cystic fibrosis (CF) patients.  Full Article

KaloBios Pharmaceuticals announces appointment of Chairman
Tuesday, 6 May 2014 04:01pm EDT 

KaloBios Pharmaceuticals Inc:Appoints Ted W. Love, M.D., as the Chairman, effective May 1.Love succeeds James I. Healy, M.D., Ph.D., who had served as a member of the board of directors and as chairman of the board since 2001.  Full Article

KaloBios Pharmaceuticals Inc announces preliminary phase 1 results in advanced hematologic malignancies with kb004, an anti-epha3 monoclonal antibody
Tuesday, 10 Dec 2013 09:00am EST 

KaloBios Pharmaceuticals Inc:Says preliminary results of an ongoing multi-center Phase 1 study of KB004, an anti-EphA3 monoclonal antibody (mAb), which the company is developing as a treatment for hematologic malignancies.Says Forty-four patients with refractory disease or who were unfit for chemotherapy have been enrolled in the dose escalation portion of the study.Says experimental patient-targeted therapeutic has been well tolerated, with initial evidence of clinical activity.  Full Article

KaloBios Pharmaceuticals Inc Announces CFO Change-Form 8-K
Wednesday, 23 Oct 2013 05:19pm EDT 

KaloBios Pharmaceuticals Inc reported in its Form 8-K that the Board of Directors (Board) of KaloBios Pharmaceuticals, Inc. (Company) appointed Herb C. Cross to the role of the Company‚Äôs Chief Financial Officer (CFO) as of October 14, 2013 and as the principal financial and accounting officer effective October 22, 2013, replacing Jeffrey H. Cooper who previously indicated his intention to retire to spend more time with family and pursue other personal interests. Mr. Cross joined the Company on September 23, 2013 and has transitioned into the Chief Financial Officer (CFO) role in coordination with Mr. Cooper.  Full Article

KaloBios Pharmaceuticals Inc Announces Closing of Public Offering And Full Exercise of Underwriters' Option To Purchase Additional Shares
Tuesday, 1 Oct 2013 03:05pm EDT 

KaloBios Pharmaceuticals Inc announced the completion of its public offering of 8,625,000 shares of common stock at $4.00 per share, which included 1,125,000 shares issued upon the exercise in full of the underwriters' option to purchase additional shares. The net offering proceeds to KaloBios were approximately $32,085,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. Leerink Swann LLC acted as sole book-running manager for the offering. William Blair & Company, L.L.C., Needham & Company LLC, and JMP Securities LLC acted as co-managers for the offering.  Full Article

KaloBios Pharmaceuticals Inc Prices Public Offering Of Common Stock
Thursday, 26 Sep 2013 07:00am EDT 

KaloBios Pharmaceuticals, Inc. (KaloBios) announced that the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $4.00 per share. The net offering proceeds to KaloBios are expected to be approximately $27,855,000 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company, but excluding any exercise of the underwriters' over-allotment option. KaloBios anticipates using the net proceeds from this offering to develop and advance its product candidates through clinical trials, as well as for working capital and other general corporate purposes. The offering is expected to close on or about October 1, 2013, subject to customary closing conditions. In addition, KaloBios has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock on the same terms and conditions, solely to cover over-allotments, if any. Leerink Swann LLC is acting as the sole book-running manager for the offering. William Blair & Company, L.L.C., Needham & Company LLC, and JMP Securities LLC are acting as co-managers for the offering.  Full Article

DIARY-U.S. MEETINGS/WEEK AHEAD

Thomson Reuters July 2, 2015 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - MONTH AHEAD Dividends Non S&P 500 - Weekly Federal Reserve events ConferenceCall/Webcast - Weekly Meetings - Weekly Xtra users can see more details on conference calls & webcasts by hovering your mouse over the RIC, right click, no click on Related Co Data, now click on Co Events. **

Search Stocks